作者: H. Starkie Camejo , X. Li , G. Van Kriekinge
DOI: 10.1016/J.PUHE.2015.02.028
关键词: Discounting 、 Family medicine 、 Cervical cancer 、 Cervical intraepithelial neoplasia 、 Gynecology 、 Genital warts 、 Quality-adjusted life year 、 Psychological intervention 、 Medicine 、 Cost effectiveness 、 Nice
摘要: Abbreviations: bHPV, AS04-adjuvanted HP warts; HPV, human papillomavirus; NICE, N HPV-6/11/16/18 vaccine. * Previous congress activities: These data h November 2013. Corresponding author. GSK Vaccines, Stock þ44 208 9902931. E-mail address: helen.j.starkie-camejo@g http://dx.doi.org/10.1016/j.puhe.2015.02.028 0033-3506/© 2015 GlaxoSmithKline Biologica cense (http://creativecommons.org/licenses/ the profiles of bHPV and qHPV differ markedly, which has triggered comparative assessment on costs benefits